Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Case of Immunotherapy Response to BRAFV600E-Mutant Lung Adenocarcinoma With Initial Resistance to Dabrafenib and Trametinib Combination Therapy.

Cancer reports (Hoboken, N.J.) - 1 Apr 2026

Okayama Yusuke, Tokito Takaaki, Shiraishi Shizuka, Takaki Reiko, Tsuneyoshi Shingo, Yamada Hiroyoshi, Nishiyama Mamoru, Sueyasu Yoshiko, Hoshino Tomoaki

Abstract excerpt

INTRODUCTION: The recommended first-line therapy for BRAF V600E mutant non-small cell lung cancer (NSCLC) is a combination of dabrafenib and trametinib. Most patients respond to the initial therapy, but some show resistance in the early stages. Additionally, immune checkpoint inhibitors (ICIs) are often used after resistance develops; however, the benefits of ICIs in patients with BRAF V600E mutant NSCLC remain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Immune Checkpoint Inhibitors

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Share to Pyridones

Share to Pyrimidinones

Source

Open in PubMed Open full text

Identifiers

PMID: 41913938
DOI: 10.1002/cnr2.70533
PMCID: PMC13140990

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Case of Immunotherapy Response to BRAFV600E-Mutant Lung Adenocarcinoma With Initial Resistance to Dabrafenib and Trametinib Combination Therapy.PMID 41913938Read ↗

Exceptionally long-lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the BRAF V600E mutation with high expression of PD-L1: A case report.Semantic proximity Read ↗

Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case ReportSemantic proximity Read ↗

MET alterations as resistance mechanisms of dabrafenib-trametinib in BRAF p.V600E mutated non-small cell lung cancer patient.Semantic proximity Read ↗

Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutationsSemantic proximity Read ↗

Promising response of dabrafenib, trametinib, and osimertinib combination therapy for concomitant BRAF and EGFR-TKI resistance mutations.Semantic proximity Read ↗

A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: A case report and literature review.Semantic proximity Read ↗

Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.Semantic proximity Read ↗

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations.Semantic proximity Read ↗

Dabrafenib-trametinib in BRAF V600-mutated non-small-cell lung cancer: a single center real world experience.Semantic proximity Read ↗

A successful pembrolizumab treatment case of lung adenocarcinoma after becoming resistant to ALK-TKI treatment due to G1202R mutation.Semantic proximity Read ↗

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.